Compare Alcon AG (ALC) vs FMC Corp (FMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs FMC Corp — how do they compare? Alcon AG trades at $66.88 (market cap $32.69B), while FMC Corp trades at $10.98 (market cap $1.45B). The key difference: Alcon AG is far larger — about 22.5× FMC Corp's market cap, and FMC Corp pays the higher dividend (2.76%). Which is the better fit depends on your goals.
| ALC | FMC | |
|---|---|---|
Market Cap | $32.69B | $1.45B |
Sector | Health | Basic Materials |
52-Week High | $92.22 | $43.90 |
52-Week Low | $62.02 | $10.80 |
Enterprise Value | $36.28B | $5.59B |
Dividend Yield | 0.54% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
FMC Corporation trades at $11.59, up 2.11% today, but remains in a bearish technical trend. The company reported a net loss of -$2.24 billion in 2025 with negative margins, though recent strategic moves include a $400 million minority investment from Tessenderlo Group and asset sales to reduce debt. Analyst consensus is mixed with a $17.00 price target, suggesting potential upside from current levels.
The outlook hinges on successful debt reduction and operational turnaround. Investment opportunity exists if cost-cutting and partnerships restore profitability, but risks include persistent revenue declines, high leverage, and competitive pressures in the agricultural sciences sector. Execution on strategic initiatives is critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
